Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2022-08-23 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
2022年半年度财务报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "北京双鹭药业股份有限公司 2022 年半年度财务报告" which translates to "Beijing SL Pharmaceutical Co., Ltd. 2022 Semi-Annual Financial Report." It covers the period from January 1, 2022 to June 30, 2022, indicating it is a half-year or interim report. The content includes consolidated balance sheets, profit statements, cash flow statements, equity changes, and detailed financial statement notes. The length is about 15,000 characters, which is substantial and contains actual financial data and analysis. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year with substantive financial data and analysis. There is no indication that this is merely an announcement or a certification, so it is not RPA or RNS. Therefore, the correct classification is IR with high confidence. H1 2022
2022-08-23 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Audit Report / Information Classification · 95% confidence The document is a special statement and independent opinion from the independent directors of Beijing Shuanglu Pharmaceutical Co., Ltd. regarding the company's external guarantees and the use of company funds by controlling shareholders and related parties. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and it provides an independent verification of compliance with relevant laws and company rules as of June 30, 2022. The document is a formal independent directors' report on specific governance and financial compliance matters, not a full annual or interim report, audit report, or earnings release. It is not a simple announcement or certification but a detailed independent opinion on a specific issue related to governance and financial oversight. This fits best under Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles or regulatory compliance verifications excluding full annual reports. H1 2022
2022-08-23 Chinese
北京双鹭药业股份有限公司2021年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an 'Annual Equity Distribution Implementation Announcement' for the year 2021 by Beijing SL Pharmaceutical Co., Ltd. It details the dividend distribution plan approved at the 2021 Annual General Meeting, including dividend amounts, record dates, and payment methods. The document does not contain full financial statements or comprehensive financial performance data but focuses solely on the dividend distribution details. The document length is 1970 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Notice of Dividend Amount (DIV).
2022-06-21 Chinese
北京双鹭药业股份有限公司2021年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2021年度股东大会决议公告" which translates to "2021 Annual General Meeting Resolution Announcement." It details the resolutions passed at the 2021 Annual General Meeting (AGM) of Beijing SL Pharmaceutical Co., Ltd., including voting results on various agenda items such as the 2021 board work report, supervisory board report, financial statements, profit distribution plan, and appointment of auditors. The document also describes the meeting attendance, voting methods, and legal opinions on the meeting's validity. The content is focused on announcing the results and resolutions of the AGM rather than providing the full annual report or financial statements themselves. The document length is 4218 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-05-26 Chinese
北京双鹭药业股份有限公司关于获得伏立康唑片药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a drug registration certificate by the National Medical Products Administration (国家药品监督管理局). It details the drug's specifications, approval process, market context, and potential impact on the company. There are no financial statements, earnings data, or management discussion of financial results. The document is an official announcement of a regulatory approval event, not a financial report or meeting material. It is relatively short (1453 characters) and serves as a formal disclosure to investors about a significant product approval. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2022-05-26 Chinese
双鹭药业法律意见
Regulatory Filings
2022-05-26 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.